BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19501160)

  • 1. Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.
    Nicolle E; Boccard J; Guilet D; Dijoux-Franca MG; Zelefac F; Macalou S; Grosselin J; Schmidt J; Carrupt PA; Di Pietro A; Boumendjel A
    Eur J Pharm Sci; 2009 Aug; 38(1):39-46. PubMed ID: 19501160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
    Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
    Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
    Zhang S; Yang X; Coburn RA; Morris ME
    Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein.
    Boccard J; Bajot F; Di Pietro A; Rudaz S; Boumendjel A; Nicolle E; Carrupt PA
    Eur J Pharm Sci; 2009 Feb; 36(2-3):254-64. PubMed ID: 18955135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
    Pick A; Müller H; Wiese M
    Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
    Tan KW; Cooney J; Jensen D; Li Y; Paxton JW; Birch NP; Scheepens A
    Mol Nutr Food Res; 2014 Nov; 58(11):2099-110. PubMed ID: 25044854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
    Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
    J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
    Nicolle E; Boumendjel A; Macalou S; Genoux E; Ahmed-Belkacem A; Carrupt PA; Di Pietro A
    Adv Drug Deliv Rev; 2009 Jan; 61(1):34-46. PubMed ID: 19135106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
    Winter E; Lecerf-Schmidt F; Gozzi G; Peres B; Lightbody M; Gauthier C; Ozvegy-Laczka C; Szakacs G; Sarkadi B; Creczynski-Pasa TB; Boumendjel A; Di Pietro A
    J Med Chem; 2013 Dec; 56(24):9849-60. PubMed ID: 24304387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Breast Cancer Resistance Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their Derivatives.
    Sjöstedt N; Holvikari K; Tammela P; Kidron H
    Mol Pharm; 2017 Jan; 14(1):135-146. PubMed ID: 28043125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
    Jabor Gozzi G; Bouaziz Z; Winter E; Daflon-Yunes N; Aichele D; Nacereddine A; Marminon C; Valdameri G; Zeinyeh W; Bollacke A; Guillon J; Lacoudre A; Pinaud N; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    J Med Chem; 2015 Jan; 58(1):265-77. PubMed ID: 25272055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.